NEWCASTLE, England,
Nov. 13, 2018 /PRNewswire/
-- Leica Biosystems, a leading provider of pathology products
and solutions, globally launched a new PD-L1 antibody for use on
their fully automated BOND IHC and ISH staining platform.
The new PD-L1 (programmed death - ligand 1) antibody uses the
MKP1A07310 (clone 73-10) expressed by UK-based Abcam on behalf of
Merck KGaA, Darmstadt, Germany,
which owns all IP rights to this antibody. It joins the recently
released ALK (anaplastic lymphoma kinase) antibody as the latest
addition to Novocastra's growing lung menu of primary
antibodies.
Leica Biosystems' Newcastle, UK
team have deep knowledge and expertise in end-to-end antibody
development and manufacturing, and have optimized these two clones
into a ready-to-use format for use on the BOND IHC and ISH staining
platform. This allows labs to perform ALK and PD-L1 testing on the
BOND system with rapid turnaround times, reliable staining and
walk-away convenience.
"Cancer remains a leading cause of death and a devastating
diagnosis for patients," said Colin
White, PhD, global vice president of Advanced Staining at
Leica Biosystems. "The PD-L1 and ALK ready-to-use antibodies are
tools that can provide valuable supporting diagnostic information
to the pathologist, with all the efficiency benefits of the BOND
system."
John Baker, senior vice president
of portfolio and business development at Abcam, added: "Our
antibody scientists have extensive experience developing the
high-quality antibodies to critical biomarkers such as PD-L1
required for use in diagnostic platforms, where using the right
antibody is crucial to patient health outcomes. Working closely
with colleagues at Leica, we succeeded in integrating this antibody
into their BOND diagnostic platform to enable accurate analysis of
PD-L1 in formalin fixed, paraffin embedded tissue."
About Leica Biosystems
Leica Biosystems is a global leader in workflow solutions and
automation, integrating each step in the workflow from biopsy to
diagnosis. Our mission of "Advancing Cancer Diagnostics, Improving
Lives" is at the heart of our corporate culture. Our easy-to-use
and consistently reliable offerings help improve workflow
efficiency and diagnostic confidence.
About Abcam
Abcam is an innovator in reagents and tools. Its purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the company offers highly validated
biological binders and assays to address important targets in
critical biological pathways. Abcam's 11 locations are in the
world's leading life science research hubs, enabling local services
and multi-language support. Founded in 1998 and headquartered in
Cambridge, U.K., the company sells
to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM:
ABC).
Media Contact: Courtney Hill,
Global Brand Marketing Specialist
Phone: 847-405-7041
Email: LBS-GlobalMarketing@leicabiosystems.com
Photo -
https://mma.prnewswire.com/media/783981/Leica_Biosystems_PD_L1.jpg